The monitoring of chimerism by PCR has become a routine diagnostic approach in patients after allogeneic bone marrow or peripheral blood stem cell transplantation. Nevertheless, a temporal correlation between molecular and hematologic assessment of engraftment has not been clearly established. To address this issue, and to determine the potential clinical implications of early kinetics of mixed chimerism, we have investigated 66 allogeneic stem cell transplantations (SCTs) in 58 pediatric patients suffering from different types of leukemia (n = 44) or non-malignant hematologic disorders (n = 14) by close molecular monitoring during the first days and weeks after transplantation. Patient-and donor-derived hematopoiesis were assessed at 1-to 3-day intervals in peripheral blood samples by PCR analysis of highly polymorphic microsatellite loci (STR-PCR). Detection of an increasing, and ultimately dominant donor-specific allelic pattern, which we defined as molecular engraftment, preceded hematologic engraftment by a median of 7 days (range 1-17 days) in all patients investigated. PCR analyses during the first days after transplantation facilitated detection of molecular engraftment according to the above definition by day +14 (range day +2 to day +14), thus permitting prediction of successful engraftment (upper limit of the two-sided confidence interval p o = 6%) while the peripheral leukocyte counts were mostly below 200/l. In three cases, however, the criteria for molecular engraftment were not fulfilled by day +14. These patients also failed to show hematologic engraftment, and required a second transplantation. Close monitoring by STR-PCR showed that graft rejection and autologous recovery can occur early and with very rapid dynamics. Molecular analysis of specific leukocyte subsets isolated by flow-sorting enabled sensitive assessment of changes in the pattern of chimerism which had escaped detection in assays using whole white blood cell (WBC) samples. This approach facilitated the identification of expanding or decreasing recipient cells, and permitted early detection of impending rejection or relapse. Moreover, monitoring of the dynamics of chimerism allowed rapid assessment of the response to therapy. Our observations provide support for the concept of initiating genotype analyses early after SCT and monitoring at rather short intervals to permit timely evaluation of clinically relevant processes, and to provide a basis for early implementation of treatment.
Introduction
Allogeneic bone marrow or stem cell transplantation (allo-BMT/allo-SCT) has been shown to produce extended diseasefree survival in a substantial number of patients who are unlikely to have their disease controlled by conventional therapeutic strategies. The emergence of new approaches to allogeneic transplantation, such as the use of umbilical cord blood, 1 nonmyeloablative SCT, 2 and haploidentical SCT from parent donors 3 might ultimately result in the availability of a donor for virtually every young patient requiring this type of treatment. With the increased accessibility of allografting, one can expect a growing demand for the clinical use of methodologies permitting the surveillance of patients during the posttransplant period. Numerous methods have been used for investigation of the patient/donor origin of hematopoietic cells after transplantation, to determine the success or failure of engraftment, and to detect recurrence of the disease. The discovery of short tandem repeat polymorphisms (STRPs) has provided a genetic system with multiple alleles and a high degree of heterozygosity, 4 permitting analysis of mixed chimerism by the polymerase chain reaction (PCR) even in the presence of very small cell numbers. The outcome of allogeneic transplantation is influenced by a number of factors including graft failure or rejection, graft-versus-host disease (GVHD), intercurrent infections, and, in patients transplanted for treatment of a malignant disorder, disease relapse. Early assessment of engraftment by detection and subsequent monitoring of chimerism in the immediate post-transplant period may be useful for prevention and management of rejection, and for detection of persistent disease and imminent disease relapse. 5 In a number of studies, molecular monitoring of chimerism has been initiated beyond the first 4 weeks posttransplant, [6] [7] [8] [9] [10] [11] whereas other reports, mostly on relatively small patient series, described the assessment of chimerism during earlier stages. [12] [13] [14] [15] [16] In the current prospective study, we have addressed the potential clinical importance of assessing the dynamics of mixed chimerism by frequent STR-PCR analysis during the first days and weeks after allogeneic transplantation, to determine the relevance of this approach for early prediction of engraftment, graft rejection or impending relapse.
Materials and methods

Patients
The patients studied were treated by allogeneic bone marrow (n = 36), peripheral stem cell (n = 29) or combined (n = 1) transplantation at St Anna Children's Hospital, Vienna, Austria between January 1996 and February 1999. Informed consent for stem cell collection and treatment was obtained. Patient characteristics are shown in Table 2 . In the patients with malignant hematologic disorders, the distribution of different types of leukemia was as follows: acute lymphoblastic leukemia (ALL; n = 26), acute myeloid leukemia (AML; n = 7), chronic myelogenous leukemia (CML; n = 6), and chronic myelomonocytic leukemia (CMML; n = 5). Among the patients with non-malignant disorders, the following entities were represented: severe aplastic anemia (SAA; n = 5), Fanconi anemia (FA; n = 3), familial hemophagocytic lymphohistiocytosis (FHL; n = 2), thalassemia (TA; n = 2), chronic granulomatous disease (CGD; n = 1), and dyserythropoietic anemia (DEA; n = 1).
Patients with immune deficiencies who were not treated with a myeloablative conditioning regimen prior to allogeneic transplantation were excluded from this study because of the different dynamics and clinical significance of mixed chimerism.
Definitions Classification of genotypes:
The following terms and abbreviations are used in this paper to describe the allelic patterns in the samples analyzed: (1) Patient genotype (PG): presence of a purely patient-specific allelic pattern. (2) Mixed chimerism (MC): presence of both patient-and donor-specific allelic patterns. (3) Donor genotype (DG): presence of a purely donor-specific allelic pattern, corresponding with complete (hematopoietic) chimerism (CC).
It is important to emphasize that the above definitions must be seen in the light of the sensitivity of the STR-PCR test system used which, depending on the selected marker and other variables of the assay, has a lower detection limit of 0.1-1%, and an average level of sensitivity between 3 and 5%
Hematologic engraftment:
Hematologic engraftment (HE) is usually defined as the first day of stable leukocyte increase above 1000/l and an absolute neutrophil count (ANC) above 500/l. In our series, the difference in time between the above findings ranged from 0 to 9 days (Table 2) . We have therefore used the more common parameter ANC for the assessment of HE.
Graft failure:
Lack of hematologic signs of engraftment within an arbitrarily defined post-transplantation time frame (beyond day +21 in this study).
Graft rejection:
Progressive disappearance of the allogeneic cells after hematologic engraftment had already taken place.
Methods
Flow cytometry:
The immunophenotype analysis and positive selection of specific immunologic cell subsets were performed as described elsewhere. 17 
DNA isolation:
Different techniques for the extraction of DNA from leukocytes were used depending on the source of material and the number of cells available. Samples from peripheral blood (PB) or bone marrow (BM) were processed as follows: after lysis of erythrocytes in a buffer consisting of 155 mM NH 4 Cl/10 mM KHCO 3 /0.1 mM EDTA, nucleated cells were pelleted at 1500 r.p.m. for 10 min. The pellet was resuspended in 200 l of 1 × PBS (phosphate-buffered saline), and subjected to DNA isolation. For samples containing less than 2 × 10 5 nucleated cells, the Dynabeads DNA DIRECT system I kit (Dynal, Oslo, Norway) was used for DNA extraction. Application of this method of DNA isolation to larger cell samples rendered the handling rather difficult, and the cost of individual extractions relatively high. We therefore carried out DNA extractions from samples of more than 2 × 10 5 cells using the QIAamp Blood Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations.
When cell subsets isolated by flow-sorting were the source of material, with total cell numbers ranging from 2 × 10 1 to 2 × 10 4 , a simple approach to isolation of DNA was pursued: flow-sorted cells collected into culture medium were spun at 1500 r.p.m. for 10 min, followed by a 1 min centrifugation at 11 000 r.p.m. After removing most of the supernatant fluid, TE buffer (10 mM TRIS/1 mM EDTA, pH 8.0) was added at 1:1 to the usually invisible cell pellet covered with residual medium (about 10 l). The cells were disrupted by two cycles of boiling and freezing at −70°C, for 10 min each. Cellular debris was spun down at 11 000 r.p.m. for 10 min, and the entire supernatant containing DNA (about 20 l) was added as template to the PCR reaction.
Marker selection for PCR genotyping:
We investigated 20 different STR (short tandem repeat) markers which had been selected from the CHLC (Cooperative Human Linkage Center) database (http://www.chlc.org) based on the following criteria: (1) heterozygosity Ͼ0.75; (2) seven or more alleles; (3) frequency of individual alleles Ͻ0.4; (4) tetranucleotide repeat; (5) no linkage with other markers tested. We ultimately selected a panel of seven STR markers found to be most suited for clinical analysis according to the following properties: (1) robustness under different (including crude) methods of DNA extraction; (2) reproducibility; (3) sensitivity; (4) low background; (5) informativeness within our patient population. The characteristics of these markers are shown in Table 1 .
In our patient population, genotyping by this panel of STR markers permitted discrimination between donor-and patientderived DNA in all instances, with a minimum of two markers displaying discernible patterns. In only two cases, the markers from the standard panel revealed patterns rendering clear identification of residual patient-derived allelic signals in the presence of mixed chimerism rather difficult, thus requiring the testing of additional STR markers for adequate follow-up.
Sensitivity of chimerism analysis:
The sensitivity achievable with different sets of primers for individual STR loci was assessed by a series of experiments using different mixtures of pretransplant cell samples and/or DNA samples derived from the donor and the recipient. The ability to detect subdominant alleles was found to be quite variable depending not only on the STR marker used, but also on other parameters such as the number of alleles co-amplified in individual PCR reactions. The highest sensitivity observed with our standard panel of markers in PCR reactions containing 100 ng of template DNA was 0.1%, when using SYBRgreen staining. In some instances, however, under suboptimal experimental conditions, the sensitivity was as low as 10%. In Table 1 , we therefore indicate the average sensitivity under standard conditions using ethidium bromide staining.
PCR reaction and electrophoresis:
All markers used were amplified under identical PCR conditions. PCR was carried out in 50 l reactions containing 200 M of each dNTP, 20 pmol of each oligonucleotide primer ( USA), and, whenever possible, 100 ng of template DNA. When analyzing samples of flow-sorted cell subsets containing between 2 × 10 1 and 2 × 10 4 cells as starting material, the entire yield of DNA was used as template in the subsequent PCR reactions. PCR was performed in a PE GeneAmp 2400 thermal cycler (Perkin Elmer) using the following cycling profile: 95°C for 10 min, two cycles of 94°C for 30 s, 65°C for 60 s, 72°C for 30 s, two cycles of 94°C for 30 s, 61°C for 60 s, 72°C for 30 s, 40 cycles of 94°C for 30 s, 58°C for 60 s, 72°C for 30 s, and a final extension step at 72°C for 7 min.
Five l of the amplification products were mixed with 3 l loading buffer (4 M Urea/50 mM EDTA/10% sucrose/0.25% bromophenol blue), and electrophoresed on 12% non-denaturing polyacrylamide gels at 35 mA for 2 h using 1 × TBE as running buffer. After separation, products were visualized by staining with ethidium bromide or SYBRgreen (Molecular Probes, Leiden, The Netherlands). The gels were evaluated by video densitometry using the Kodak Digital Science System with the 1D Image Analysis Software (Kodak, Rochester, NY, USA).
Statistics
The analyses were performed using the Statistical Analysis System (SAS) 6.12 software package (SAS Institute, Cary, NC, USA). The Mann-Whitney test was used to evaluate the correlation between the time from molecular to hematologic engraftment and clinical parameters including diagnosis, donor type, stem cell source, T cell depletion, and conditioning regimen.
The Wilcoxon signed rank test was applied to assess the correlation between molecular engraftment (ME) and the leukocyte count at this point or the WBC kinetics prior to ME.
Results
In this single-center prospective study, 66 consecutive allogeneic bone marrow or stem cell transplantations in 58 pediatric patients suffering from different types of leukemia or nonmalignant hematologic disorders (Table 2) were investigated by serial STR-PCR genotype analysis during the early posttransplant course. After identification of a suitable STR marker facilitating clear discrimination between patient-and donorderived alleles, peripheral blood samples were investigated by PCR at 1-to 2-day intervals during the first week after transplantation, and at 2-to 3-day intervals during the following weeks, until day +28. Thereafter, the intervals were usually extended to 3 to 7 days depending on the dynamics of chimerism observed.
Early kinetics of chimerism, molecular engraftment and prediction of hematologic engraftment
Peripheral blood samples collected within the first 24 h after allograft infusion often revealed the presence of mixed chimerism (MC), indicating the persistence of residual recipient cells and circulating donor cells. In a large proportion of cases (n = 34), we observed continuous MC during the first days and weeks post-transplant until or beyond hematologic engraftment. This finding apparently reflected a temporal overlap between the presence of residual and newly produced donor cells in peripheral blood. In six of the patients displaying MC on the first post-transplant day(s), circulating donor cells subsequently decreased below the detection limit, resulting in the observation of pure patient genotype (PG) for 1 or more days, before reappearance of MC indicated the presence of apparently newly produced donor-derived hematopoietic cells in peripheral blood. Most of the remaining cases with successful engraftment (n = 19) revealed a recipient-specific allelic pattern for 1 to 9 days post-transplant, before the observation of MC indicated release of donorderived cells into peripheral blood. In a few individual patients, we observed unique patterns of kinetics, such as the continuous presence of pure or nearly pure DG from the first day post-transplant, or transition from PG to pure DG without a detectable intermediate stage of MC. Although the majority of the patients were monitored using the same marker (GATA22G05; see Table 1 ) which displays a rather constant level of sensitivity, an effect of variable detection limits on these observations cannot be excluded.
In general, serial STR-PCR analysis revealed a gradual increase of the donor-specific allelelic signal ( Figure 1 ) which became dominant over the recipient-specific allele(s) by day +14 (median +8; range +2 to +14). The day on which dominance of donor-derived leukocytes could first be demonstrated in peripheral blood by STR-PCR analysis preceded the detection of hematologic engraftment (HE) by a median of 7 days (range 1-17 days) (Figure 2 ). The possibility of predicting successful HE by STR-PCR analysis prompted us to introduce the term molecular engraftment. On the basis of our observations, we have established the following preliminary definition: molecular engraftment (ME) = first appearance of dominance of the donor-specific allelic pattern in total leukocyte preparations from peripheral blood.
As an additional prerequisite for the diagnosis of ME, the dynamics of mixed chimerism with increasing donor-specific signal during the preceding days ( Figure 1 ) should be documented by STR-PCR analysis in order to ensure that newly produced rather than persisting donor cells are being detected. In some instances (n = 5) in which continuous MC with dominance of donor-derived cells in peripheral blood was demonstrable upon infusion of the allograft, ME was defined as the first appearance of complete donor genotype (DG) in total WBC samples from peripheral blood. In this subset of patients, ME preceded HE by a median of 8 days (range 3-12 days).
There was no concordance between the peripheral leukocyte count or its dynamics and molecular engraftment according to the above definitions. In the cohort of patients studied, the median WBC count at the time of ME was 100/l (range 10-500/l), with only five patients displaying a WBC count of more than 200/l at the time of ME (Table 2) .
In all patients with successful HE studied, pure DG (ie complete chimerism; CC) was detected by day +28 (median: +11). Detection of CC commonly preceded hematologic engraftment by a time span ranging between 1 and 15 days; the detection of CC coincided with HE in four cases, and occurred later than HE in seven instances.
Early detection of graft failure or rejection
The majority of patients studied had successful hematologic engraftment. In all these cases, molecular engraftment was detectable between days +2 and +14 (median: +8). Three of TX, transplantation; ME, molecular engraftment; CC, complete chimerism (pure donor genotype); L, leukocytes; ANC, absolute neutrophil count; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; SAA, severe aplastic anemia; FA, Fanconi anemia; FHL, familial hemophagocytic lymphohistiocytosis; TA, thalassemia; DEA, dyserythropoietic anemia; CGD, chronic granulomatous disease; ATG, anti-thymocyte globulin (horse); ALG, anti-lymphocyte globulin (rabbit);
TBI, total body irradiation; Bu, busulfan; VP16, etoposide; Flu, fludarabine; Pred, prednisone; OKT3, Moab against T cells; Cy, cyclophosphamide; Thio, thiotepa; TLI, total lymphoid irradiation; MUD, marrow unrelated donor; MSD, matched sibling donor; MMFD, mismatched family donor; BM, bone marrow; PBSC, peripheral stem cell transplantation; CR-AW, in complete remission-alive and well; GVHD, graft-versus-host disease; MOF, multiorgan failure; NA, not achieved; ND, not determinable; ND*, not determinable because ME was not achieved or could not be asessed, ND**, not determinable because patient received granulocyte concentrates; ND***, not determinable because the leukocyte number was never Ͻ300/l.
Figure 1
Example of early kinetics of chimerism as determined by serial STR-PCR analysis during the first days after allogeneic transplantation. P, patient; D, donor. The negative and positive numbers indicate the respective days before and after transplantation. Zero and zero plus (0+) indicate the day of SCT before and after allograft infusion, respectively. Marker: GATA22G05.
Figure 2
Probability of molecular and hematologic engraftment after allogeneic SCT. The Kaplan-Meier plot based on the patients investigated reveals that the probability to permit detection of molecular engraftment (ME) (solid line) was 80% by day +10, and 100% by day +14 in all patients who later had successful hematologic engraftment. By contrast, the probability of hematologic engraftment (HE) (dotted line) by day +10 and +14 was Ͻ10% and Ͻ40%, respectively. Patients who failed to engraft hematologically either had no ME (n = 2) or had ME beyond day +14 (n = 1; ME on day +17).
the patients investigated had no signs of ME by day +14 (Table 2 ; Nos 3, 11, 31 -1.TX), and indeed failed to engraft hematologically. Two of them (Nos 3, 31) received a second transplantation from a different donor, and engrafted successfully. The third patient (No. 11) was retransplanted from the same donor, but rejected the graft. Finally, a third allogeneic SCT from a different donor was successful in terms of engraftment.
Graft rejection in patients who already had achieved molecular and hematologic engraftment was observed in three instances. All three patients had received T cell-depleted peripheral blood stem cell (PBSC) transplants. As shown in Figure 3 , rejection of the allograft can occur early and with
Figure 3
Dynamics of graft rejection in a patient with CML documented by serial STR-PCR analysis (see Results). Note that the extremely rapid changes in the pattern of mixed chimerism were observed during an early stage post-transplant while the patient was still in severe aplasia. Marker: GATA84B12. extremely rapid dynamics. In the patient presented (Table 2 ; No. 35 -1.TX), close monitoring of total WBC samples from peripheral blood revealed reversion from DG to virtually pure PG within 48 h. This change was documented by STR-PCR analyses between days +14 and +16 post-transplant while the patient was still in aplasia with peripheral WBCs around 500/l. After confirming this observation during the following days both in PB and BM, the patient was successfully retransplanted from the same donor. Early rejection was detected by serial STR-PCR analysis in another patient (Table 2 ; No. 52 -1.TX) by demonstrating reappearance of MC in total leukocytes from PB on day +20 after a period of pure DG during the preceding days. The diagnosis of graft rejection was supported by concordant dynamics within the CD4 + and CD8 + lymphocyte subsets isolated from PB by flow-sorting, which displayed a change from MC to pure PG on day +20. The WBC count at this stage was 2.9 × 10 3 /l with an ANC of 1.9 × 10 3 /l. The findings provided a basis for early retransplantation from the same parent donor which resulted in successful hematologic engraftment with the presence of pure DG in PB already on day +7, but the patient died a few months later from organ toxicity. Serial STR-PCR analysis permitted detection of impending graft rejection in another of the patients studied (Table 2 ; No. 11 -2.TX): in this case, pure DG was observed on day +11, but MC reappeared on day +16. The autologous allelic signal within the total WBC fraction from PB increased rather gradually over a period of nearly 6 weeks. In agreement with the suspected graft rejection, STR-PCR analysis of CD4 + and CD8 + lymphocyte subsets revealed persistence of a pure PG. The WBC count showed increasing numbers until day +28, and remained in the range of 2 × 10 3 /l until day +50; thereafter, the leukocyte numbers decreased rapidly over the following 10 days. The patient was retransplanted again, this time from a different parental donor, and had successful engraftment, but died 6 months later from an adenovirus infection (Table 2 ; No. 11 -3.TX).
Detection of residual disease and impending relapse
In our series, STR-PCR analysis of total leukocyte preparations showed MC for up to 28 days post-transplant. STR-PCR investigation of various leukocyte subsets isolated by flow-sorting revealed that in most instances MC was caused by persisting recipient T cells, either CD4
+ and/or CD8 + , which are known to survive the intensive conditioning regimens applied. 18, 19 A somewhat surprising finding was the frequent detection of CD34
+ cells of recipient origin in FACS-sorted populations from peripheral blood. These cells were observed in almost all patients studied and remained detectable up to 70 days post-transplant. The possibility of monitoring the presence of these cells was mostly limited by the increasing numbers of donor-derived cells of various lineages, which ultimately reduced the relative proportion of this cell subset to an extent that prevented isolation by flow-sorting and assessment of the origin by genotyping. These cells were morphologically different from normal CD34 + cells, and turned out to be nonclonogenic in standard assays. 17 It is conceivable that they represent severely damaged stem cells, but their relatively long persistence in peripheral blood is intriguing and remains to be elucidated.
In patients allografted for a malignant hematologic disorder, surveillance by molecular analysis of chimerism permitted the detection of imminent disease relapse by the reappearance of a recipient-specific allelic signal after a period of complete 2067 chimerism (Table 2 ; Nos 9, 20, 22, 39, 43, 44) or by the detection of gradually increasing recipient-specific allelic signal in a patient displaying MC (Table 2 ; No. 16). The malignant origin of the patient-derived cells detected has been assessed by monitoring the dynamic changes of the allelic pattern within total leukocytes or particular leukocyte subsets, or by employment of other techniques directed at the detection of diseasespecific markers. [20] [21] [22] In one of these patients, who experienced a relapse during the first weeks following allogeneic peripheral blood SCT (No. 16), we were able to document increasing recipient chimerism in serial DNA samples derived from total leukocyte preparations. In two other instances, the reappearance of MC in peripheral blood or bone marrow samples heralded recurrence of the disease (Nos 22, 43) . The investigation of whole WBC fractions, however, has not been sensitive enough in other instances to permit timely detection and monitoring of residual, possibly malignant autologous cells, and to facilitate the surveillance of dynamic changes of potential clinical relevance. Investigation of specific leukocyte subsets expected to harbor residual leukemic cells, if present, permitted the assessment of impending relapse in some (Nos 9, 20, 39, 44), but not all (Nos 19, 31) patients by the reappearance of recipient genotype after a period of complete chimerism. In one of the patients with CML (No. 39), serial investigation of total WBC samples from peripheral blood revealed continuous complete chimerism starting at a very early stage post-transplant. The patient tested bcr-abl positive by RT-PCR analysis which is an expected finding during the first months after allografting, 23 and serial quantitative investigation of bcr-abl transcripts 20 had not been performed at this point. The assessment of chimerism within various cell subsets isolated from peripheral blood and bone marrow also showed pure DG within the first 6 weeks after transplantation. Thereafter, a switch from DG to PG was observed within the CD19 + cell fraction, while all other cell subsets analyzed (CD3
The presence of this apparently small cell population of recipient origin was not sufficient to result in the detection of MC within total leukocyte samples tested at this stage. The appearance of autologous precursor B cells in peripheral blood of this patient was suggestive of incipient lymphoid blast crisis, and indeed, a bone marrow aspiration at that time already permitted confirmation of the diagnosis upon morphological examination. The patient has received a second allograft from the same donor, but died from relapse shortly thereafter. The problem of sensitivity in the surveillance of residual autologous cells can be illustrated by the observations in another of the patients studied who had been treated by allogeneic SCT for multiple relapse of a B cell precursor ALL (Table 2 ; No. 1). In this case, STR-PCR analysis of DNA extracted from total leukocyte preparations both from peripheral blood and bone marrow revealed continuous CC starting from day +10, but the analysis of individual leukocyte subsets from the bone marrow and peripheral blood showed the presence of autologous cells in the CD19
+ fraction (Figure 4 ). This minor cell population, which had escaped the detection when DNA from total leukocytes was analyzed, was the only one displaying a patient genotype. The autologous cells detected very likely represented residual leukemic cells, thus providing a basis for discontinuation of the immunosuppressive treatment to enhance the graft-versus-leukemia effect. This approach was apparently successful as documented by serial analysis of individual leukocyte subsets that ultimately revealed complete chimerism within all populations, including the CD19
+ fraction (Figure 4 ). 
Discussion
In this series, we have investigated early dynamics of mixed chimerism in 66 consecutive, allogeneic bone marrow or peripheral blood stem cell transplantations in pediatric patients with various types of leukemia and different non-malignant disorders. In all patients investigated, who had successful hematologic engraftment, serial analysis of WBC samples from peripheral blood revealed molecular engraftment (ME) according to a definition we propose herein, within 2 weeks after infusion of the allograft. The kinetics of increasing donor chimerism at this early stage post-transplant is apparently produced by committed progenitor cells, 24 and the correlation with sustained engraftment due to pluripotent stem cells remains to be elucidated. The detection of molecular engraftment preceded hematologic engraftment by a median of 7 days, and the peripheral WBC count at the time of ME was below 200/l in most instances. This observation was independent from factors such as the conditioning regimen, the source of transplanted cells or T cell depletion. However, there was a significant difference (P = 0.009) between the time from ME to HE in different diagnostic subsets: in patients with CML/CMML the median time span was 12 days, as opposed to a median of 7 days in patients with ALL/AML or non-malignant disorders. A borderline significant, but clinically not relevant difference, was observed between patients treated by PSCT vs BMT (P = 0.047) in whom the median time span between ME and HE was 8.5 and 6.5 days, respectively.
Patients who failed to show molecular engraftment by day +14 were later classified as non-engrafters by hematologic criteria. It will be interesting to evaluate in larger series whether the absence of molecular engraftment within a certain time span post-transplant is predictive of graft failure. It is conceivable that the state of MC on day +14 will turn out to be a useful parameter for therapeutic considerations in certain instances. At this stage, the options may include the application of growth factors in patients with slow onset of donor hemopoiesis, 25 the administration of additional donor hematopoietic stem cells or early retransplantation to avoid unnecessarily long exposure of the patient to the risks of prolonged aplasia.
With regard to graft rejection, our observations indicate that this complication may occur early after allografting and the dynamics of this process may be very rapid. The assessment of MC during the very early post-transplant period may permit the detection of changes indicative of rejection, namely the relative increase or recurrence of recipient-specific allelic signals in the cell samples analyzed. In patients who rejected the allograft, investigation of chimerism within specific leukocyte subsets revealed that the cells of recipient origin contributing to the shift in MC were present in the CD3
+ (ie T cell) fraction.
Serial STR-PCR analysis in the CD3
+ subset showed either MC with gradual increase of the recipient-specific signal or a complete change to recipient genotype. The assessment of dynamics of chimerism within this cell subset is important because persisting recipient T cells are often observed during the early post-transplant period, and may contribute to MC in total leukocyte samples from peripheral blood without necessarily indicating imminent graft rejection. Timely detection of incipient allograft rejection may have important therapeutic implications. These include the modulation of immunosuppressive treatment, the administration of donor lymphocyte infusions (DLI) or a second allogeneic transplantation. 21, 26 If the latter approach is performed very early after molecular detection of impending graft rejection, before extensive autologous recovery, in particular of CD3 + cells, had taken place, it may be possible to avoid another course of chemotherapeutic conditioning. This approach could prevent unnecessary toxicity and improve the long-term outcome. In view of the fact that T cell-depleted and mismatched SCT are associated with the greatest risk of graft rejection, this subset of patients is likely to have the greatest benefit from close monitoring of chimerism and its dynamics.
In patients who receive allogeneic SCT or BMT for treatment of a malignant hematologic disorder, detection of increasing recipient chimerism within leukocyte samples derived from peripheral blood may be indicative of incipient relapse, 27 or graft rejection with autologous recovery. 5, 28 For early detection of disease recurrence, the relatively low sensitivity of chimerism analyses within whole leukocyte preparations may present a problem. Moreover, the detection of increasing recipient chimerism within total WBC samples does not provide any information on the identity of cells contributing to this finding. The analysis of chimerism within specific cell subsets isolated by flow-sorting reveals the type and origin of the expanding cells, and significantly increases the sensitivity in detecting a residual population of interest. It is possible to isolate cell subsets that represent as little as 1% of the entire cell population, thus improving the sensitivity of subsequent genotype analysis by up to two logs. This approach permits the assessment of whether the proliferating cells display an immunophenotype suggestive of the leukemic clone. 5, 9, 29 Since genotype analysis only provides indirect evidence for the presence of a leukemic cell population, other techniques permitting the detection of specific disease markers such as fusion transcripts, or clonality markers such as immunoglobulin gene or T cell receptor rearrangements, 21, 22 should be employed whenever possible to confirm the leukemic origin of the expanding cells.
Serial analysis by STR-PCR during the first days and weeks after allograft infusion revealed that clinically relevant changes requiring therapeutic intervention may occur at an early stage of the post-transplant period, while patients are still in aplasia with peripheral WBCs around or below 500/l. It is not generally accepted, however, that molecular monitoring of chimerism very early after allogeneic transplantation may provide useful information. In extension of earlier reports, [12] [13] [14] [15] [16] our observations indicate that a relatively late onset of molecular monitoring is associated with an increased probability of missing important changes and losing the possibility of timely modification of treatment. However, optimum time of onset and adequate frequency of genotype testing, which will likely depend on parameters such as the source and type of the allograft, the conditioning regimen, the underlying disease, and the particular clinical situation, remain to be firmly established in future studies.
